Special Issue

Diagnosis and Management of Advanced Prostate Cancer

Message from the Guest Editor

Prostate cancer represents the most common malignancy among men in western countries. The therapeutical landscape of prostate cancer has changed enormously in the last decade, including improvements in imaging modalities, genomic profiling. development of new targeted therapies, their sequencing, and the multimodality approach. In this Special Issue, we will focus on innovations in prostate cancer management, starting with developments in imaging that will influence and shape the prostate cancer treatment strategy. The role of genomic profiling is increasing and influencing the individualization of therapy in real clinical practice. Getting to know the disease biology is of utmost importance for any further steps. Advances in biomarker assessment will optimize future therapeutical decisions to improve the outcome of prostate cancer. New findings in the field of systemic therapy in both metastatic hormone-sensitive and castration-resistant cancer are more than welcome. We intend for this Special Issue to be informative for all prostate cancer researchers.

Guest Editor

Dr. Hana Študentová

Department of Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University, 771 47 Olomouc, Czech Republic

Deadline for manuscript submissions

closed (31 October 2023)



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.7 Indexed in PubMed



mdpi.com/si/138476

Diagnostics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.3 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the second half of 2024).

